**Investigation of P120catenin Expression in Human Basal Cell Carcinoma of the Skin**

Vladimír Bartoš¹,*, Milada Kullová²

**ABSTRACT**
Background: P120(ctn) is a specific membranous adhesion protein, that maintains the stability of intercellular junctions. An altered expression of p120(ctn), either reduced in the cell membrane or increase in the cytoplasm, plays a crucial role in carcinogenesis. No research has analysed the expression of p120(ctn) in basal cell carcinoma (BCC) of the skin so far. Therefore, we immunohistochemically studied p120(ctn) in a set of cutaneous BCCs in order to determine, whether there is difference in the expression pattern related to the histologic subtypes and tumor growth characteristics. Material and Methods: The study group consisted of 38 BCCs categorized into low-risk (non-infiltrative) subgroup (8 superficial and 12 nodular subtypes) and high-risk (infiltrative) subgroup (10 nodular-infiltrative and 8 infiltrative subtypes). Specific monoclonal antibody against p120(ctn) was used for staining. Results: Overall, there were 12 cases (31.6%) with normal preserved and 26 cases (68.4%) with abnormal p120(ctn) expression. In superficial, nodular, nodular-infiltrative and infiltrative subtypes, abnormal p120(ctn) immunoreactivity was found in 37.5% (3/8), 41.7% (5/12), 100% (10/10) and 100% (8/8), respectively. We have confirmed a strong correlation between the expression of p120(ctn) and both given, non-infiltrative and infiltrative BCC growth phenotypes. In the latter subgroup, almost all lesions showed diffusely reduced membranous staining, of which five also manifested an aberrant immunoreactivity in the cytoplasm. This cytoplasmic positivity occurred solely at the invasive front of the infiltrative tumor formations. Conclusion: Our results showed that decreased membranous expression of p120(ctn) was a frequent event in human cutaneous BCC and it was associated with infiltrative growth phenotype. Considering that nearly half of the BCCs with non-infiltrative growth pattern also exhibited reduced membranous expression, aberrant cytoplasmic immunoreactivity of p120(ctn), which was found exclusively in the high-risk BCC variants, can more reliably reflect and predict biological behaviour and malignant potential.

**KEYWORDS**
basal cell carcinoma; biological behaviour; P120catenin

**AUTHOR AFFILIATIONS**
¹ Department of Pathology, Faculty Hospital in Žilina, V. Spanyola 43, Žilina, 012 07, Slovakia
² Department of Dermatovenerology, Faculty Hospital in Žilina, V. Spanyola 43, Žilina, Slovakia
* Corresponding author: Björnsonova 3/5, Martin, 036 01; Slovakia; e-mail: vladim.bartos@gmail.com

Received: 28 December 2016
Accepted: 23 March 2017
Published online: 7 June 2017

Acta Medica (Hradec Králové) 2017; 60(1): 32–36
https://doi.org/10.14712/18059694.2017.48
© 2017 The Authors. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
INTRODUCTION

P120catenin (p120(ctn)) is a specific cell-cell adhesion protein, which is linked to a wide variety of oncogenes and tumor suppressors, such as Src kinases, receptor tyrosine kinases and phosphatases, E-cadherin, β-catenin, RhoGTPases, Kaiso, and Wnt signaling effectors. A major role of p120(ctn) is to serve as a cadherin “gatekeeper”. Under normal conditions, p120(ctn) is expressed in the cell membrane and binds directly to the juxtamembrane domain of E-cadherin. This stabilizes cadherin and maintains the stability of intercellular adhesions. In contrast, when p120(ctn) is phosphorylated, it is dissociated from the cadherin tail, leading to cadherin internalization and consequently, the weakening of the cell-cell junctions. As a result, p120(ctn) expression is reduced in the cell membrane and increased in the cytoplasm. Therefore, the subcellular distribution of p120(ctn) significantly modulates adhesion status of the cells and plays an important role in the carcinogenesis.

IMMUNOHISTOCHEMISTRY

Biopsy samples were routinely processed and immunohistochemical stained for calponin according to manufacturer’s instructions. Shortly, representative 4-μm tissue sections applied on silanized slides were baked for 2 hours in an oven at 56 °C. Then the sections were deparaffinized in xylene, rehydrated in series of descending ethanol concentrations and treated with microwaves in Dako Target Retrieval Solution (0.01 M citrate buffer, pH 6.0) for 20 minutes. The endogenous peroxidase activity was blocked with 3% hydrogen peroxide. Subsequently, specific monoclonal mouse antibody against p120catenin (clone MRQ-5, DAKO, dilution 1:25) was used for staining. After incubation at ambient temperature, post primary antibody was applied and an immunoreaction was visualised by means of the DAB (3,3′-diaminobenzidine) detection chromogen solution. Slides were counterstained with Mayer’s hematoxylin, dehydrated, mounted and finally evaluated in the light microscope. Positive reaction on epithelium of eccrine glands served as internal control.

RESULTS

In our series, p120(ctn) was expressed in 36 tumor samples with variable quantitative range and intensity. Two BCCs (one nodular and one nodular-infiltrative subtype) showed a completely negative staining. Overall, there were 12 cases (31.6%) with normal preserved and 26 cases (68.4%) with abnormal (including two lesions with negative) p120(ctn) expression. In the latter subgroup, almost all lesions showed diffusely reduced membranous staining, of which five (all of them comprising infiltrative growth pattern) also manifested an aberrant immunoreactivity in the cytoplasm. This cytoplasmic positivity was grouped comprised 20 low-risk (non-infiltrative) BCC subtypes (superficial and nodular). The second subgroup comprised 18 high-risk BCCs with (at least focal) infiltrative growth pattern (mixed nodular-infiltrative and infiltrative subtypes).
only focal, however, it occurred exclusively at the invasive front of tumor nests. No nuclear immunoreactivity was detected. Immunohistochemical status of p120(ctn) expression seemed to be related to histopathological BCC subtypes. In superficial, nodular, nodular-infiltrative and infiltrative subtypes, abnormal p120(ctn) immunoreactivity was found in 37.5% (3/8), 41.7% (5/12), 100% (10/10) and 100% (8/8), respectively. We have confirmed a strong correlation between the expression of p120(ctn) and both given, low-risk and high-risk BCC subgroup (p = 0.001). While non-infiltrative histologic subtypes of BCC manifested a normal preserved expression in the majority of the cases (60%, 12/20) (Figure 1 and 2), all BCCs with infiltrative growth features (100%, 18/18) showed abnormal type of p120(ctn) expression, including a strong cytoplasmic immunoreactivity (Figure 3 and 4). A summary of the immunohistochemical findings in our set of BCCs investigated is presented in Table 1.

<table>
<thead>
<tr>
<th>BCC subtype</th>
<th>N</th>
<th>Membranous expression of p120(ctn)</th>
<th>Aberrant cytoplasmic expression of p120(ctn)</th>
</tr>
</thead>
<tbody>
<tr>
<td>superficial</td>
<td>8</td>
<td>normal 5 (62.5%) reduced 3 (37.5%)</td>
<td>no 8 (100%) present 0 (0 %)</td>
</tr>
<tr>
<td>nodular</td>
<td>12</td>
<td>normal 7 (58.3%) reduced* 5 (41.7%)</td>
<td>no 12 (100%) present 0 (0 %)</td>
</tr>
<tr>
<td>nodular-infiltrative</td>
<td>10</td>
<td>normal 0 (0%) reduced* 10 (100%)</td>
<td>no 8 (80.0%) present 2 (20.0%)</td>
</tr>
<tr>
<td>infiltrative</td>
<td>8</td>
<td>normal 0 (0%) reduced 8 (100%)</td>
<td>no 5 (62.5%) present 3 (37.5 %)</td>
</tr>
</tbody>
</table>

Fig. 1: Preserved diffuse membranous expression of p120(ctn) in superficial BCC (original magnification 200×).

Fig. 2: Preserved diffuse membranous expression of p120(ctn) in nodular BCC (original magnification 100×).

Fig. 3: Virtually completely absent expression of p120(ctn) in infiltrative BCC (original magnification 40×).

Fig. 4: Strong cytoplasmic expression of p120(ctn) within the tumor cells in infiltrative BCC. Some cells also show a concomitant immunoreactivity in the cell membrane (original magnification 200×).
BCC of the skin is histomorphologically and phenotypically very heterogeneous on a cellular level. It possesses some unique features, such as slow local growth, strong stroma-dependency, and virtual absence of metastases (16,17). Although it generally pursues a favourable clinical course, some cases show an aggressive behaviour, rapidly infiltrating deeper tissue structure and leading to treatment difficulties with local recurrences (16,17). Many molecular markers have been studied in cutaneous BCC until now (17), however, it is still not clearly understood, which of them are directly responsible for aggressive tumor behaviour and conversely, which potentially prevent cancer cells to metastasize.

This paper describes immunochemical changes in the expression status of cell-cell adhesion molecule p120(ctn) in a panel of 38 human BCCs of the skin. We have found that more than two thirds of the cases were accompanied by abnormal p120(ctn) expression. Therefore, a loss of normal membranous p120(ctn) expression is frequent histopathologically in cutaneous BCC. Of note, it has been found to be associated with infiltrative tumor growth. Our results are similar to those reported for other cancers (2–12, 18, 19) which suggests that the decrease or loss of p120(ctn) in the cell membrane plays a crucial role in tumorigenesis and a rising malignant potential. Interestingly, only a few cases concurrently exhibited an aberrant strong cytoplasmic immunoreactivity. This somewhat contradicts with many previous studies (4, 5, 8, 12, 20–22) which have shown that the transition of p120(ctn) from the cell membrane to the cytoplasm (or even into the nuclei) in various malignancies is associated with potentially invasive phenotype and disease progression and it might be more relevant prognostic indicator. In our study, among 26 BCCs with reduced or lost membranous immunostaining, only 5 lesions manifested apparent cytoplasmic accumulation of p120(ctn), which was not very extensive. Although this feature seemed to be linked with infiltrative growth character of BCC, due to small number of such cases we did not evaluate a statistical significance. Since as far as we know, this is the first study addressing immunohistochemical investigation of p120(ctn) in cutaneous BCC, we had no opportunity to compare our results with another observations. At this point, it seems likely that an invasive growth of BCC is accompanied by loss of membranous p120(ctn) expression, however, usually without concomitant accumulation in the cytoplasm. This may be a special molecular feature of this human malignancy. A similar situation is known, for example, in the breast tumors, in which the lesions of ductal and lobular origin exhibit distinct expression patterns of p120(ctn). While the lobular neoplasms show a markedly increased cytoplasmic immunoreactivity without discernible cell membrane staining, ductal neoplasias show reduced membrane expression without appreciable cytoplasmic accumulation (18, 19).

In conclusion, our study showed that decreased membranous expression of p120(ctn) was a frequent event in human cutaneous BCC and it was associated with infiltrative growth phenotype. Further, aberrant cytoplasmic immunoreactivity occurred only in a few cases, but it was found exclusively in the high-risk BCC variants at the invasive front of the infiltrative tumor formations. Considering that nearly half of the BCCs with non-infiltrative growth pattern also exhibited reduced membranous expression of p120(ctn), cytoplasmic positivity can more reliably reflect and predict biological behaviour and malignant potential. Further investigations are needed to elucidate the mechanism and role of p120(ctn) in BCC biology and our present study may provide the basis for them.

ACKNOWLEDGEMENTS

The authors would like to thank Dr. Daniela Melova for her outstanding educational and technical assistance.

REFERENCES


